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Cytomegalovirus (CMV) is the most common cause of intrauterine infection, occurring in up to 2% of all live births. Most women
are asymptomatic or experience nonspecific symptoms, which can lead to long-term sequelae in newborns including neurological
impairment, hearing loss, and mental retardation. A 41-year-old woman (G6 P2), with a medical history of epilepsy, presented
for her routine anomaly scan at 20 + 4/40. A single finding of echogenic bowel was noted on ultrasound which prompted a full
investigation. A repeat ultrasound only five days later demonstrated progressive changes, which included bilateral ventriculomegaly
with oedema of the posterior ventricular wall, periventricular hyperechogenicity, and enlargement of the cisterna magna. CMV
DNA was detected at amniocentesis. Ultrasound findings are not diagnostic for CMV with only 11–15% of at-risk fetuses being
identified. Unfortunately, these findingsmay be the only indication of an abnormality.There is a well-documented lack of awareness
surrounding CMV and screening is not routinely offered. Given the risk to the pregnancy of CMV and to subsequent pregnancies,
simple education at the start of a pregnancy could significantly reduce the incidence of maternal CMV.
1. Introduction
CMV is the most common cause of intrauterine infection
[1–3] with an incidence of 0.3–2% in all live born infants
[1, 2, 4–6]. Infected women often present with nonspecific
signs and symptoms, but the majority are asymptomatic [6].
Approximately 10% of newborns show symptoms at birth
[1, 3–5] but this increases to 20–30% if their mothers were
infected in the first trimester [7]. There is a 30% mortality in
the affected infants and 90%will have long-term neurological
impairment [4, 5]. Of the asymptomatic neonates, 10% will
develop permanent sequelae, including hearing loss and
mental retardation [1, 3–5].
CMV infection can be a result of a primary infection,
a reinfection with a new strain, or a reactivation of the
residing virus [1, 5, 7]. The rate of primary infection from
mother to child is approximately 40% (range 24–75%), as
opposed to 1–2.2% in the case of reinfection (secondary)
with a new strain [6]. The impact of primary infection on
the fetus however is more significant [1, 3, 4]. The latency
between primary and secondary infection and the detection
of these differences on ultrasound are still under debate [1].
It appears that the fetal infection is more common when
maternal infection occurs later in pregnancy, but the severity
of the infection is higher before 18 weeks of gestation [5].
Transmission of the virus to the fetus can, however, occur
weeks after maternal primary or secondary infection [7].
The ultrasound findings in CMV are not diagnostic
as many features are shared with other conditions [1]. In
addition, some studies have demonstrated that these findings
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Figure 1: Echogenic bowel.
are only present in up to one-third of the cases [1]. Lazzarotto
et al. [6], in fact, only found that ultrasound detected not
more than 5%of the infected fetuses. Furthermore, newultra-
sound features to help in the diagnosis of intrauterine CMV
have not been identified yet [1]. Asmost countries do not offer
universal CMV screening in pregnancy, ultrasound moni-
toring is important as it is currently the only way of monitor-
ing and assessing the prognosis of a fetus infected by CMV
[2–4, 6]. Around 50% of the infected fetuses after a primary
infection will be affected and present with both extracerebral
and cerebral features on ultrasound and up to one-third
demonstrate cerebral features only [1].
Anti-CMV IgG avidity is currently the most reliable test
to identify primary infection in a pregnant woman [6]. Low
avidity indicates an acute or primary infection as opposed to
high avidity which indicates no current or recent infection
[6]. Anti-CMV IgG avidity performed before the 16–18th
week of pregnancy will identify all women at risk to have
an infected fetus with a reported 100% sensitivity. After 20
weeks of gestation, the sensitivity is drastically reduced [6].
Amniocentesis is recommended between 21 and 22 weeks
of gestation; CMV is a slow replication virus and will take
up to 6–9 weeks before it is excreted in the fetal urine, in
amounts large enough to be detected in the amniotic fluid
[1, 6]. Conducting an invasive procedure too early could in
fact result in a false negative result [1].
Ultrasound is therefore a useful adjunct in predicting the
likelihood of postnatal disease. It can also be used as a prog-
nostic parameter as the positive predictive value of ultra-
sound increases 2-fold when results from invasive testing
indicate fetal infection [1, 4]. We present an unusual case
where ultrasound was essential to guide the diagnosis of con-
genital CMV.
2. Case Study
A 41-year-old Gravida 6, Para 2, presented in her first
trimester with an unremarkable blood serology and a low
combined screening risk for trisomy. Her obstetric history
included 3 first-trimester miscarriages and a caesarean sec-
tion and vacuum delivery, both at term. She was on medica-
tion for epilepsy but otherwise fit and well. Echogenic bowel
was detected at her routine anomaly scan at 20 weeks
Figure 2: Bilateral ventriculomegaly with oedema of the posterior
ventricular wall and periventricular hyperechogenicity.
Figure 3: Enlargement of the cisterna magna.
and 4 days. She was referred to the Fetal Medicine Unit,
where a repeat ultrasound, performed the following day,
confirmed the findings of an isolated echogenic bowel with
no other obvious structural anomalies (Figure 1). She was
offered screening for a number of conditions known to be
associated with echogenic bowel, including fetal aneuploidy,
cytomegalovirus, toxoplasmosis, parvovirus, and cystic fibro-
sis. The couple declined an amniocentesis at this point.
The blood tests revealed that the couplewere both carriers
for the cystic fibrosis gene. In addition, the CMV IgG was
positive, whilst the IgMwas negative.This was checked retro-
spectively against her stored booking bloods, which revealed
a positive IgG and IgM.The IgG antibody avidity was investi-
gated and found to be low. Following these results, the
couple proceeded with an amniocentesis at 22 weeks of gesta-
tion. The scan at this gestation still only revealed isolated
echogenic bowel. The karyotype was normal but CMV DNA
was detected in the amniotic fluid.
However, only 5 days later, a further scan revealed
new findings which included bilateral ventriculomegaly with
oedema of the posterior ventricular wall, periventricular
hyperechogenicity (Figure 2), and enlargement of the cisterna
magna (Figure 3). The progressive changes on ultrasound
indicated a poor prognosis for the fetus, and the couple termi-
nated the pregnancy at 24 weeks of gestation. They declined
a postmortem, but histopathology of the placenta demon-
strated extensive lymphocyte infiltration with occasional
CMV inclusions suggestive of chronic villitis due to the virus.
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3. Discussion
3.1. Effect of Gestational Age. Information regarding the effect
of gestational age on the outcome of the congenital infection
is important as it is helpful in determining strategies for pre-
vention, diagnosis, and treatment of infection in pregnancy
[7]. As in our case, echogenic bowel and ventriculomegaly
are the most common findings, but, despite this, they may
only be identified in 11.8–15% of fetuses at risk [7]. Borderline
ventriculomegaly is most common, but severe cases have
been reported [4]. Lissencephaly is often described from
24 weeks of gestation and mega cisterna magna from 26
weeks of gestation [2, 4]. Other common features include
periventricular hyperechogenicity, also identified in this case
[2, 4]. Intraventricular synechia are seen in 50% of the cases,
as well as intercranial calcifications in the periventricular
area, brain parenchyma, cerebellum, and the corpus callosum
[7]. Most report punctiform calcifications in the cerebellum,
but linear calcifications have also been described [4]. In the
transverse cerebellar plane, vermian defects can be identi-
fied [4]. Another classic feature of CMV in pregnancy is
thalamic hyperechogenicity secondary to vasculitis, which
is commonly referred to as the “candlestick sign” [2, 4].
Picone et al. [3] describe an occipital horn cyst, which has not
been demonstrated in any other infective process, and they
speculate that this may be unique to CMV infection in utero.
3.2. Pathogenesis. Understanding the development of the
brain in utero is crucial to correlating findings seen on
ultrasound scan with the exact time that maternal infection
has occurred. The CMV virus, which is a double-stranded
DNA virus, has a predisposition for the neuroblasts of
the germinal matrix. This forms in the seventh week of
gestation [8–10]. Infection before the eighth week of gestation
leads to lissencephaly, when CMV interferes with neuronal
migration [4], whereas infection between 18 and 24 weeks
of gestation results in focal dysplastic cortices [2]. The
cerebellum ends its formation by 18 weeks of gestation, and,
therefore, the presence of cerebellar anomalies is suggestive
of maternal infection prior to this [2]. Periventricular cysts
and germinalmatrix necrosis are seen in the second trimester,
whereas fetuses with normal gyral patterns and periventricu-
lar echogenicities are probably injured in the third trimester
[2]. Neuronal growth is complete by 26 weeks of gestation, so
infections later in pregnancy have a little effect [10]. Similar
to our case, Malinger et al. [2] described one case of rapid
changes occurringwithin aweek, from solely intraventricular
adhesions to periventricular irregular patterns in the germi-
nal matrix adjacent to the occipital horns.
Subependymal cystic lesions or calcifications, which
develop during the second trimester, are thought to be the
result of the necrotizing inflammatory effect of CMV on the
subependymal germinal matrix of the lateral ventricles [2, 8].
Furthermore, it is thought that the scattered cerebral calcifi-
cations seen in the basal ganglia and thalami may correlate
to the severity of the disease [8]. The encephaloclastic effect
of the virus disturbs the cell proliferation in the developing
brain, causing brain atrophy, and dilated ventricles may be
seen as a result. Ventriculomegaly may also be a result of
vasculitis or inflammatory exudates obstructing the flow of
cerebrospinal fluid [8, 9].
3.3. Prognosis. It appears that children with congenital CMV
infection were more likely to have serious sequelae if their
mothers were infected earlier in the pregnancy. 23% of the
infants were symptomatic when CMV infection occurred in
the first trimester, compared to 11.4% in mothers infected
after the first trimester [7]. There was also a trend towards
greater abnormal neurological ultrasound findings being
identified in those mothers infected in the first trimester.
26% of the cases of CMV diagnosed in pregnancy showed
abnormal findings if the mothers were infected before 20
weeks of gestation, as opposed to 6.2% after 20 weeks of
gestation [11]. Romanelli et al. [5] did not find any correlation
between ultrasound findings and fetal infection, and Guerra
et al. [1] stated that only fetuses with a severe disease will
demonstrate obvious ultrasound abnormalities. The authors,
however, do agree with Malinger et al. [2] that any com-
bination of features on ultrasound do indicate a poorer
prognosis. Unfortunately, because of the pathophysiology of
CMV, several weeks can elapse before ultrasound features
become obvious, and sometimes thismay be the case until the
third trimester [1]. It is therefore recognised that fetal cerebral
features on ultrasoundmay not appear until significantly after
maternal infection has occurred [4].
The findings on fetal MRI are fairly well correlated with
ultrasound features [5], but the MRI is considered better
in detecting abnormal gyration [1]. It may be useful if
ultrasound imaging is inconclusive or difficult secondary to
an unfavourable fetal lie ormaternal habitus [12].When there
are no cerebral findings, MRI is not indicated [3], and, in our
case, the findings were so severe, and MRI would not have
changed management.
3.4. Subsequent Pregnancies. When counseling the parents
following a primaryCMV infection, it is important to provide
information regarding the risks of CMV in subsequent
pregnancies; the transmission rate can vary from 0.2% to 7%
[13–15]. Of those infected, up to 8% of the infants may have
neurological sequelae [15]. Reinfection with a different strain
of CMV can occur in up to 62% of the seropositive mothers
[16]. This is complicated by the fact that infected infants
born to mothers with recurrent CMV infection are rarely
symptomatic at birth making it more difficult to diagnose
clinically [14, 15]. Transmission of CMVoften occurs through
saliva and the urine of infected children; therefore, although
the risk cannot be eliminated, education on hygiene and
behavioural measures should be provided to all women
regardless of the serological status [6].
3.5. Prevention and Treatment. It is important to prevent
CMV to reduce the burden of morbidity associated with
congenital infection [12]. However, neither the Royal Col-
lege of Obstetricians and Gynaecologists nor the National
Collaborating Centre for Women’s and Children’s Health
recommends routine CMV screening of all pregnant women.
At present, treatment has been focused on reducing the
adverse outcomes in the infected children after birth [12].
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Studies using Ganciclovir following birth to prevent late-
onset hearing loss have been controversial, as there have been
high losses to follow-up and serious side effects, including
haematological toxicity, have been demonstrated [12]. Oral
Valaciclovir has been used to try and treat symptomatic CMV
in utero, but no significant benefits with treatment have been
demonstrated [12]. Similarly, research has been carried out
into the antenatal administration of hyperimmune globulin
therapy to try and reduce either the rate of transmission or
the severity of the disease in an infected fetus [5].This prepa-
ration uses pooled human plasma from screened donors
to provide a therapeutic alternative for congenital CMV
to termination of pregnancy or conservative management,
whilst avoiding the potential fetal toxicity of antivirals such
as Ganciclovir [12]. However, its efficacy has not been proven
in any randomised controlled trials, and there have not been
any long-term follow-up studies to look at adverse sequelae
to the neonates in mothers who have been treated with the
immunoglobulin [1, 12].
3.6. Awareness Campaigns. There is a well-documented lack
of awareness surrounding CMV; Cannon et al. [17] found
that only 7% of men and 13% of women had heard of CMV
infection and mean to prevent the spread of the disease [18,
19]. Due to the asymptomatic nature of CMV infection and
lack of public awareness, the mechanisms of prevention are
currently centred around education andhygiene. Studies have
shown that simple education at the start of a pregnancy could
significantly reduce the incidence of maternal CMV [18, 20,
21]. CMV Action [22] is one of the nonprofit organisations
based in the United Kingdom to raise the public’s awareness
of congenital CMV and publicise any new CMV research
findings through their website and social media. They offer
support to families that may have been affected by the
condition and are working with medical professionals with
an interest in the field.
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